Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that affects over 51
million individuals globally. The β-secretase (BACE1) enzyme is responsible for the …

Abstract Alzheimer's disease (AD), the most common cause of age-dependent dementia, is
one of the most significant healthcare problems worldwide. Aggravating this situation, drugs …

Alzheimer's disease (AD) is a chronic neurological condition that has become a leading
cause of cognitive decline in elder individuals. Hardly any effective medication has been …

A major hallmark of Alzheimer's disease (AD) is the deposition of amyloid‐beta (Aβ) plaques
in the brain. Sequential cleavage of amyloid precursor protein by BACE 1 and γ‐secretase …

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most
common form of dementia in the world. Studies report the presence of extracellular amyloid …

Abstract β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the
potential of disease-modifying treatment for Alzheimer's disease (AD). Since 2014, major …

Alzheimer's disease (AD) is the most common age-dependent neurodegenerative disease
which impairs cognitive function and gradually causes patients to be unable to lead normal …

Alzheimer's disease (AD) is a very serious public health problem. Currently, there is no
effective treatment for AD. Among the many biochemical targets for AD drug development, β …

Background Alzheimer's disease (AD) is the most common form of dementia, the number of
affected individuals is rising, with significant impacts for healthcare systems. Current …

Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common
type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of …